SCHEMBL6715526

SCHEMBL6715526

CCOC(=O)Cc1cc2c(OC)cccc2[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 5/20 0.60
MTNR1B P49286 5/20 0.60
FLT3 P36888 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
IDO1 P14902 1/20 0.47
KDM4E B2RXH2 1/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 2/20 0.46
DUSP3 P51452 1/20 0.46
PTPN5 P54829 1/20 0.46
PTPN11 Q06124 1/20 0.46
CTDSP1 Q9GZU7 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9587954 0.84 SMN1; SMN2 (0.50) MTNR1AMTNR1BSMN1; SMN2IDO1KDM4E
SCHEMBL28586501 0.83 MTNR1A (0.65) MTNR1AMTNR1BFLT3IDO1KDM4E
SCHEMBL5188478 0.82 DRD2 (0.44) MTNR1AMTNR1BFLT3SMN1; SMN2KDM4E
SCHEMBL9587713 0.81 ALDH1A1 (0.43) MTNR1AMTNR1BSMN1; SMN2KDM4ELMNA
SCHEMBL3935995 0.78 KDM4E (0.57) SMN1; SMN2KDM4ELMNAPOLBMEN1
SCHEMBL699482 0.78 FLT3 (0.60) MTNR1AMTNR1BFLT3SMN1; SMN2IDO1
SCHEMBL25267 0.78 MTNR1A (0.62) MTNR1AMTNR1BFLT3IDO1KDM4E
SCHEMBL24104984 0.78 MTNR1A (0.61) MTNR1AMTNR1BFLT3IDO1POLB
SCHEMBL24583898 0.77 MTNR1A (0.63) MTNR1AMTNR1BFLT3IDO1POLB
SCHEMBL170083 0.76 HSD17B10 (0.56) MTNR1AMTNR1BSMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E MTNR1A 46/4885MTNR1B 35/4885FLT3 4225/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 MTNR1A 288/4885MTNR1B 312/4885FLT3 3332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.